Nadege Sanon, APRN
Family · Fort Myers, FLNPI 1740846195
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,882, 9.0 times the $208 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $91.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$485
- Boehringer Ingelheim$344
- Bayer$337
- Paratek Pharmaceuticals, Inc.$336
- Sanofi-aventis U.S. LLC$313
- Shionogi Inc$270
- plus $4K from 31 others
What the payments were for
- Food & beverage$5,962100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 6 | $485 |
| Boehringer Ingelheim | 3 | $344 |
| Bayer | 3 | $337 |
| Paratek Pharmaceuticals, Inc. | 3 | $336 |
| Sanofi-aventis U.S. LLC | 4 | $313 |
| Shionogi Inc | 3 | $270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $250 |
| Viiv Healthcare Company | 2 | $245 |
| Insmed, Inc. | 3 | $245 |
| Eisai Inc. | 2 | $244 |
| Alnylam Pharmaceuticals Inc. | 2 | $244 |
| Lilly USA, LLC | 3 | $222 |
| AbbVie | 4 | $151 |
| Aimmune Therapeutics, Inc. | 2 | $140 |
| Astellas Pharma US Inc | 1 | $140 |
| Neurocrine Biosciences, Inc. | 1 | $136 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Merck | 1 | $125 |
| OPKO Pharmaceuticals, LLC | 1 | $125 |
| Smith+Nephew | 1 | $125 |
| Tris Pharma Inc | 1 | $122 |
| Novo Nordisk | 1 | $120 |
| Gilead | 1 | $119 |
| Exact Sciences | 1 | $117 |
| Axsome Therapeutics, Inc. | 1 | $97 |
| Xeris Pharmaceuticals, Inc. | 1 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $95 |
| Teleflex LLC | 1 | $92 |
| Amgen | 1 | $92 |
| Medtronic | 1 | $92 |
| United Therapeutics Corporation | 1 | $86 |
| Neurelis, Inc. | 1 | $63 |
| Axonics, Inc. | 1 | $52 |
| Pfizer | 1 | $49 |
| Biogen | 1 | $43 |
| Johnson & Johnson | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$344
- Kerendia$337
- VERQUVO$250
- CAPLYTA$250
- Fetroja$245
- NUZYRA$245
- Leqembi$244
- Rezzayo$242
- Brinsupri$232
- Veozah$140
- INGREZZA$136
- ONPATTRO$125
- Austedo XR$125
- MOUNJARO$125
- Rayaldee$125
- CABENUVA$125
- COLLAGENASE SANTYL$125
- Vabomere$122
- Dyanavel XR$122
- Quillivant$122
How this compares
$5,962 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 11 | $3,978 |
| Fosfomycin Tromethamine | 11 | $2,380 |
| Vancomycin Hcl | 18 | $1,768 |
| Doxycycline Hyclate | 42 | $1,066 |
| Rifampin | 11 | $820 |
| Linezolid | 16 | $755 |
| Cefadroxil | 11 | $453 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $212 |
| Ciprofloxacin Hcl | 22 | $177 |
| Fluconazole | 15 | $124 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $92 |
Paid to pharmacies, not to this prescriber.
Other family in Fort Myers
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.